Ongoing Ebola transmission in the Democratic Republic of the Congo, with over 4,500 confirmed cases and 2,100 deaths as of mid-August, anchors trader sentiment around regional containment. The Bundibugyo strain outbreak, declared a PHEIC in May, has already spilled into Uganda (20 cases, outbreak declared over in July) and produced at least one export to France, while neighboring countries face elevated importation risk. Traders track surveillance data, border controls, and any new laboratory-confirmed detections through year-end, noting the absence of approved vaccines or treatments for this strain as a key uncertainty factor. Historical patterns show Ebola clusters often remain localized when response ramps up quickly, yet rapid case growth in eastern DRC provinces continues to shape probabilities for additional countries reporting cases before December 31.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$32,579 Vol.
Dec 31, 2026
South Sudan
63%
Rwanda
30%
Burundi
32%
United States
20%
Canada
28%
Kenya
54%
India
12%
Republic of the Congo
30%
Nigeria
51%
Ethiopia
51%
Somalia
34%
China
21%
$32,579 Vol.
South Sudan
$1,794 Vol.
63%
Rwanda
$2,128 Vol.
30%
Burundi
$200 Vol.
32%
United States
$9,621 Vol.
20%
Canada
$1,086 Vol.
28%
Kenya
$195 Vol.
54%
India
$732 Vol.
12%
Republic of the Congo
$11,921 Vol.
30%
Nigeria
$25 Vol.
51%
Ethiopia
$65 Vol.
51%
Somalia
$71 Vol.
34%
China
$2,787 Vol.
21%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.Ongoing Ebola transmission in the Democratic Republic of the Congo, with over 4,500 confirmed cases and 2,100 deaths as of mid-August, anchors trader sentiment around regional containment. The Bundibugyo strain outbreak, declared a PHEIC in May, has already spilled into Uganda (20 cases, outbreak declared over in July) and produced at least one export to France, while neighboring countries face elevated importation risk. Traders track surveillance data, border controls, and any new laboratory-confirmed detections through year-end, noting the absence of approved vaccines or treatments for this strain as a key uncertainty factor. Historical patterns show Ebola clusters often remain localized when response ramps up quickly, yet rapid case growth in eastern DRC provinces continues to shape probabilities for additional countries reporting cases before December 31.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Market Opened: May 22, 2026, 12:35 PM ET
Volume
$32,579End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.Ongoing Ebola transmission in the Democratic Republic of the Congo, with over 4,500 confirmed cases and 2,100 deaths as of mid-August, anchors trader sentiment around regional containment. The Bundibugyo strain outbreak, declared a PHEIC in May, has already spilled into Uganda (20 cases, outbreak declared over in July) and produced at least one export to France, while neighboring countries face elevated importation risk. Traders track surveillance data, border controls, and any new laboratory-confirmed detections through year-end, noting the absence of approved vaccines or treatments for this strain as a key uncertainty factor. Historical patterns show Ebola clusters often remain localized when response ramps up quickly, yet rapid case growth in eastern DRC provinces continues to shape probabilities for additional countries reporting cases before December 31.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$32,579End Date
Dec 31, 2026Market Opened
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...Ongoing Ebola transmission in the Democratic Republic of the Congo, with over 4,500 confirmed cases and 2,100 deaths as of mid-August, anchors trader sentiment around regional containment. The Bundibugyo strain outbreak, declared a PHEIC in May, has already spilled into Uganda (20 cases, outbreak declared over in July) and produced at least one export to France, while neighboring countries face elevated importation risk. Traders track surveillance data, border controls, and any new laboratory-confirmed detections through year-end, noting the absence of approved vaccines or treatments for this strain as a key uncertainty factor. Historical patterns show Ebola clusters often remain localized when response ramps up quickly, yet rapid case growth in eastern DRC provinces continues to shape probabilities for additional countries reporting cases before December 31.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions